Previous close | 73.90 |
Open | 74.05 |
Bid | 72.60 x 100 |
Ask | 73.08 x 100 |
Day's range | 72.62 - 74.70 |
52-week range | 49.24 - 94.57 |
Volume | |
Avg. volume | 181,050 |
Market cap | 1.308B |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | 24.36 |
EPS (TTM) | 2.99 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Jul 2010 |
1y target est | 116.80 |
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.